Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple myeloma (MM). CR is one of the best predictors of long-term survival. These three studies were selected for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008. Highlights included:

-- VELCADE, cyclophosphamide, and dexamethasone (CyBorD) demonstrated a

CR rate of 46 percent prior to transplant and 72 percent

post-transplant

-- VELCADE, DOXIL and dexamethasone (PAD or VcDD) prior to transplant

showed a CR rate of 21 percent which increased to 59 percent

post-transplant

-- VELCADE, lenalidomide and dexamethasone (VRD) showed a CR rate of 35

percent at maximum planned dose and a 100 percent overall response

rate.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The goal of first-line therapy is to rapidly achieve the deepest and most durable response possible," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "VELCADE based combinations produce among the highest CR rates that are similar to those achieved by high dose therapy and transplantation. These very strong results underscore the critical role of VELCADE in patients with newly diagnosed multiple myeloma."

Efficacy of Induction with CyBorD in Newly Diagnosed Multiple Myeloma (Abstract #8517)

This study of CyBorD was designed to determine response in patients with newly diagnosed multiple myeloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... No-Cost, Noninvasive Tool Detects Risk for Undiagnosed Diabetes, ... Years, ALEXANDRIA, Va., April 28 A ... undiagnosed diabetes,identify whether they likely have the disease ... and complications associated with this now,epidemic illness, according ...
... Schering-Plough Corporation,(NYSE: SGP ) today reported ... ongoing Phase II study of boceprevir, its investigational ... with chronic,hepatitis C virus (HCV) genotype 1 were ... Association for the Study of the Liver (EASL). ...
Cached Medicine Technology:Drug Combo Could Lower Diabetes Complications and Costs 2Drug Combo Could Lower Diabetes Complications and Costs 3Drug Combo Could Lower Diabetes Complications and Costs 4Drug Combo Could Lower Diabetes Complications and Costs 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... for patients with Type V AC joint injuries, according ... study, presented today at the American Orthopaedic Society for ... personnel returned to duty faster when surgery was not ... patients, with 7 receiving surgical treatment and 17 receiving ...
(Date:3/28/2015)... Lately the student-athlete experience has undergone ... around the NCAA. In a March episode of ... a spectrum of universities and sports shed light on ... panel consists of athletes who have competed for universities ... and field, baseball, and volleyball. They discuss the value ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... News) -- About half of the 30 million Americans ... about potential health risks before heading abroad, new research ... travelers departing the United States at Boston Logan International ... or middle-income nations. Only 54 percent of those travelers ...
... News) -- Older brothers are more likely than older sisters to ... at 195 children, aged 10 to 12, who had siblings that ... with older brothers were more likely to report being bullied at ... younger brother or sister. Older sisters were more likely to bully ...
... Chinese on EurekAlert! Chinese . BETHESDA, ... scientists and clinicians in the human genetics field will convene to ... Genetics 60th Annual Meeting, which will be held November 2-6, 2010, ... this year,s meeting will feature research on the application and use ...
... THURSDAY, Nov. 4 (HealthDay News) -- Annual screening for lung ... current or former heavy smokers by 20 percent, a major ... Americans who fall ill from lung cancer -- the nation,s ... could be significant, experts noted. And, unexpectedly, annual CT ...
... (Nov. 4, 2010) Nine years ago, scientists at ... occurring in the molecular makeup of the most aggressive ... they found that a specific protein called laminin-411 plays ... new blood vessels to support its growth and spread. ...
... Most mutations in the genes of the Salmonella ... And this is the case regardless whether they lead to ... by Uppsala University scientists in an article being published today ... have examined the impact of mutations on the rate of ...
Cached Medicine News:Health News:Many U.S. Travelers Uninformed About Health Risks Abroad 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 3Health News:Studies validate use of family health history as gold standard in disease risk assessment 4Health News:Studies validate use of family health history as gold standard in disease risk assessment 5Health News:Studies validate use of family health history as gold standard in disease risk assessment 6Health News:Studies validate use of family health history as gold standard in disease risk assessment 7Health News:Studies validate use of family health history as gold standard in disease risk assessment 8Health News:Studies validate use of family health history as gold standard in disease risk assessment 9Health News:Studies validate use of family health history as gold standard in disease risk assessment 10Health News:Studies validate use of family health history as gold standard in disease risk assessment 11Health News:CT Scans Seem to Lower Lung Cancer Death Rates 2Health News:CT Scans Seem to Lower Lung Cancer Death Rates 3Health News:CT Scans Seem to Lower Lung Cancer Death Rates 4Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 2Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 3Health News:Unexpectedly small effects of mutations in bacteria bring new perspectives 2
... Clear Plus™ Uncuffed Endotracheal Tube w. FlexiSlip™ Stylet, ... use. A quality Rusch endotracheal tube with a ... you time and storage space. The stylet has ... It is designed with a soft distal tip ...
... stylet inside. Sterile, Latex Free, Single ... tube with a preloaded Slick® Stylet ... time and storage space. The stylet ... and has a stopper to help ...
... PVC. Murphy eye-nasal. High volume/low pressure ... For improved surgical access. Designed to ... incorporating a preformed curvature. Thin-walled, large ... adapts to the anatomical situation at ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. No cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Medicine Products: